Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.
As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.
In an interview to CNBC-TV18, Shashank Sinha, Managing Director of Strides Shasun spoke about the results and his outlook for the company.
Going forward, the pharma company is going to to focus on its B2C business and the high cash generating verticals, he says.
In an interview to CNBC-TV18, Shashank Sinha, Group CEO of Strides Shasun spoke about the results and his outlook for the company.
In an interview to CNBC-TV18, Arun Kumar, Executive VC and MD of Strides Shasun said the company may sell off its API unit after enhancing its value.
Strides Shasun for the first quarter reported net profit at Rs 41.79 crore and total income stood at Rs 870 crore versus Rs 955 crore quarter on quarter.
CNBC-TV18‘s Ekta Batra talks about what to expect from Strides Shasun‘s numbers today.
Sales are expected to decrease by 4.7 percent Q-o-Q (up 58.3 percent Y-o-Y) to Rs 955.0 crore, according to Religare Research.
Third quarter performance was hit due to floods in Chennai but there has been a strong pullback in the last quarter, he said, adding growth in business from regulated markets like Australia and the US have helped, said Arun Kumar, Executive VC & MD at Strides Shasun.
The growth trajectory is very strong going forward and the company has all the necessary engines to grow the business at 20-25 percent CAGR, said Arun Kumar, MD, Strides Shasun.
Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.
Group CFO of Strides Arcolab TS Rangan tells CNBC-TV18 that the company is betting on Agila to drive growth in FY13.
Stride Arcolab has declared its first quarter results. The company's Q1 consolidated net profit was up 2.26% at Rs 40.7 crore versus Rs 39.8 crore. For 2011, he says, “A median EBITDA of 21% is the one we are looking at the increased sales of Rs 2,200 crore.”
Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Strides Arcolab March quarter sales are expected to go up by 28.3% at Rs 479.1 crore, year-on-year, (YoY) basis.
Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.